TRIMTECH Therapeutics

Protein degradation
#Protein degradation #Seed funding #TRIMTECH Therapeutics

TRIMTECH raises $47m for protein degradation portfolio 

TRIMTECH Therapeutics has raised an additional $14 million in seed funding, bringing total investment for the company’s targeted protein degradation portfolio to $47 million.  TRIMTECH has demonstrated its TRIMTAC and TRIMGLUE degraders can selectively degrade toxic protein aggregates and oligomers while leaving the functional monomeric forms of these proteins intact to… Read More

#Business & Investment #News

#Biotech #Financing #TRIMTECH Therapeutics

TRIMTECH Therapeutics appoints new Chair of the Board 

Biotechnology company TRIMTECH Therapeutics has appointed Alison Lawton as Chair of the Board as the company moves to advance its portfolio of disease-modifying therapies.  Lawton arrives at TRIMTECH with more than 35 years of global pharma and biotech leadership expertise, leading global regulatory strategy for numerous product approvals and gaining extensive… Read More

#News

#E3 ligases #Investment #Life sciences #Neurodegenerative disorders #TRIMTECH Therapeutics

Part 1: A day exploring Cambridge’s life science scene

DDW’s Megan Thomas went to Cambridge, UK, to learn more about what’s happening in this life science epicentre. She spoke with a number of local companies and attended events, the first of which she writes about here: A conversation with Nicola Thompson, CEO of TRIMTECH Therapeutics. E3 ligases to expand… Read More

#Business & Investment #Exclusive Content

Neuroscience
#Neurodegenerative disorders #Neuroscience #Protein degradation #Start-ups #TRIMTECH Therapeutics

Start-up harnesses protein degradation for neurodegeneration

TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, has closed a $31 million seed funding round.   The investment will support further development of the company’s pipeline of central nervous system (CNS) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs.  … Read More

#Business & Investment #News #Start-up Zone